Bavarian Nordic

Further investment made in smallpox vaccine production

Published in Oncology Business Week, April 3rd, 2005

Bavarian Nordic announced that it will embark on further significant investments to extend production for its Imvamune smallpox vaccine program, as well as accelerate product development activities in its smallpox, HIV and cancer vaccine programs in the U.S. and Europe.

Peter Wulff, president and CEO, commented, "We view the biodefense market as any other market, where if you want to be a leader you have to invest in your own future. This latest decision is part of our long-term strategy that we embarked upon in 1998 to develop and supply a safe smallpox vaccine.

he increased interest that we have now seen in our Imvamune smallpox vaccine from...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Oncology Business Week

Source: Oncology Business Week (2005-04-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry